World's leading clinical conference on bone, joint and muscle health
Programme
Friday April 17th - CEST Timezone
08:00 - 09:00
Auditorium 1
Sponsored Breakfast Symposium
* See details on the Sponsored Satellite Symposia page
* See details on the Sponsored Satellite Symposia page
08:00 - 09:00
Auditorium 2
Sponsored Breakfast Symposium
* See details on the Sponsored Satellite Symposia page
* See details on the Sponsored Satellite Symposia page
08:00 - 09:00
Non-Sponsored Symposia
08:00
MR - D9
Musculoskeletal Aging: where East meets West
Chairperson: Elaine Dennison
Chairperson: Elaine Dennison
08:00
MR - D9
Musculoskeletal aging in the oldest old: when East meets West
08:00
MR - D9
The ROAD study: an overview
08:00
MR - D9
The SALSA study: an overview
08:00
MR - D9
How does musculoskeletal health and its determinants in East and West differ?
08:00
MR - D8
Cardiovascular Comorbidities in Osteoporosis: WHO Report
Chairperson: Peter Ebeling
Chairperson: Peter Ebeling
08:00
MR - D8
Move to Improve: Osteoporosis, Cardiovascular Risk, and the Role of Exercise in Healthy Aging
08:00
MR - D8
Bone Appétit: Influence of Cardiovascular Disease on Musculoskeletal Health: A Key Role for Nutrition?
08:00
MR - D8
A Model of Atherosclerotic Calcifications as a Consequence of Osteoporosis
08:00
MR - D8
Q&A
08:00
MR - D3
The metabolic profile of psoriatic disease. Obesity, musculoskeletal manifestations and management
Chairperson: Panagiotis Athanassiou
Chairperson: Panagiotis Athanassiou
08:00
MR - D3
Psoriatic disease
08:00
MR - D3
Psoriatic disease and metabolic syndrome
08:00
MR - D3
Psoriatic disease and obesity
08:00
MR - D3
Psoriatic disease and treatment
08:00
MR- D4
Standardizing Periprosthetic DXA in Hip and Knee Arthroplasty: From Variability to Robust Data
Chairpersons: Jose Francisco Torres-Naranjo, Cristina Ojeda-Thies
Chairpersons: Jose Francisco Torres-Naranjo, Cristina Ojeda-Thies
08:00
MR- D4
Why Periprosthetic DXA Needs Standardization: Evidence, Variability, and the RAND/UCLA Process
08:00
MR- D4
From Pixels to Protocols: A Practical Framework for High-Quality Periprosthetic DXA
08:00
MR- D4
Interpreting Perprosthetic BMD: Precision, Longitudinal Change, and Therapy-Aware Flags
08:00
MR - D1
Capture the Fracture® - Building High-Quality Fracture Liaison Services: Practical Lessons from Global Experience
Chairperson: Maria Luisa Brandi
Chairperson: Maria Luisa Brandi
08:00
MR - D1
The FLS history in Italy: A decade of action
08:00
MR - D1
Learning from peers and building a strong FLS community – the Japanese experience
08:00
MR - D1
A set of variables for the assessment of Fragility Fracture patients in an FLS environment in Latin America (Country Specific Datasets)
08:00
MR - D1
Q&A
08:00
MR - D2
Effects of mineral waters on muscle and bone
Chairpersons: Giovanni Iolascon, Silvia Migliaccio
Chairpersons: Giovanni Iolascon, Silvia Migliaccio
08:00
MR - D2
Nutritional determinants of Musculoskeletal Health
08:00
MR - D2
Mineral Waters and the Musculoskeletal System
08:00
MR - D2
The Role of Mineral-Rich Waters in Managing Musculoskeletal Fragility: preliminary data from the FOCUS study
08:00
MR - D2
Discussion
08:00 - 09:00
MR - C1
ESCEO-DVO Joint Symposium: Current highlights in Osteology
Chairpersons: Ralf Schmidmaier, Manju Chandran
Chairpersons: Ralf Schmidmaier, Manju Chandran
08:00
MR - C1
One for all? Scoring of vertebral fractures?
08:20
MR - C1
Treatment induced osteoporosis in women with breast cancer - the updated position statement
08:40
MR - C1
Fracture and Osteoporosis - Riskfactor, Endpoint, Complication,Treatment
08:00 - 09:00
MR - D12
ESCEO Symposium: Update of the 2017 recommendations for the use of Hyaluronic Acid injections in patients with knee osteoarthritis: a patient-centered experts’ consensus
Chairpersons: François Rannou, Ali Mobasheri
Chairpersons: François Rannou, Ali Mobasheri
08:00
MR - D12
Efficacy of IAHA in osteoarthritis
08:00
MR - D12
Safety of IAHA in osteoarthritis
08:00
MR - D12
New perspectives in the use of IAHA for the management of osteoarthritis
08:00
MR - D12
Discussion leaders
09:00 - 10:30
Auditorium 1
Scientific Session I
Chairpersons: Charlotte Beaudart, Peter Ebeling
Chairpersons: Charlotte Beaudart, Peter Ebeling
09:00
Auditorium 1
Plenary Lecture
Management of very high fracture risk in the context of a lifelong osteoporosis treatment plan
Management of very high fracture risk in the context of a lifelong osteoporosis treatment plan
09:30
Auditorium 1
Oral communications selected from abstracts
OC1 - PREDICTIVE VALUE OF BMD FOR HIP AND OTHER FRACTURES: A META-ANALYSIS TO UPDATE FRAX
OC1 - PREDICTIVE VALUE OF BMD FOR HIP AND OTHER FRACTURES: A META-ANALYSIS TO UPDATE FRAX
09:40
Auditorium 1
Oral communications selected from abstracts
OC2 - LIFE EXPECTANCY FOLLOWING FIRST DXA - ARE MEN REFERRED TOO LATE? AN ANALYSIS OF THE 1900-1960 BIRTH COHORT
OC2 - LIFE EXPECTANCY FOLLOWING FIRST DXA - ARE MEN REFERRED TOO LATE? AN ANALYSIS OF THE 1900-1960 BIRTH COHORT
09:50
Auditorium 1
Oral communications selected from abstracts
OC3 - EARLY INITIATION OF OSTEOPOROSIS TREATMENT AFTER FRACTURE REDUCES SECONDARY FRACTURES IN ADULTS AGED ≥75 YEARS
OC3 - EARLY INITIATION OF OSTEOPOROSIS TREATMENT AFTER FRACTURE REDUCES SECONDARY FRACTURES IN ADULTS AGED ≥75 YEARS
10:00
Auditorium 1
Oral communications selected from abstracts
OC4 - TIMING OF ANTI-OSTEOPOROTIC TREATMENT INITIATION AFTER VERTEBRAL FRACTURE AND RISK OF NEW FRACTURE IN A FLS MODEL
OC4 - TIMING OF ANTI-OSTEOPOROTIC TREATMENT INITIATION AFTER VERTEBRAL FRACTURE AND RISK OF NEW FRACTURE IN A FLS MODEL
10:10
Auditorium 1
Oral communications selected from abstracts
OC5 - THE NUMBER NEEDED TO TREAT (NNT) ANALYSIS: A CLINICAL CONTEXT FOR THE TREATMENT-RELATED CHANGE IN TOTAL HIP BONE MINERAL DENSITY: THE ASBMR-SABRE PROJECT
OC5 - THE NUMBER NEEDED TO TREAT (NNT) ANALYSIS: A CLINICAL CONTEXT FOR THE TREATMENT-RELATED CHANGE IN TOTAL HIP BONE MINERAL DENSITY: THE ASBMR-SABRE PROJECT
10:20
Auditorium 1
Oral communications selected from abstracts
OC6 - ADHERENCE TO CARDIOVASCULAR RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB: INTERIM RESULTS FROM A EUROPEAN MULTI-DATABASE DRUG UTILISATION STUDY
OC6 - ADHERENCE TO CARDIOVASCULAR RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB: INTERIM RESULTS FROM A EUROPEAN MULTI-DATABASE DRUG UTILISATION STUDY
10:30 - 12:15
Auditorium 1
Scientific Session II
Chairpersons: Radmila Matijevic, Etienne Cavalier
Chairpersons: Radmila Matijevic, Etienne Cavalier
10:30
Auditorium 1
Presentation of the 2026 ESCEO Medal of Excellence
10:40
Auditorium 1
Plenary Lecture
Barriers and facilitators for orthogeriatric success
Barriers and facilitators for orthogeriatric success
11:10
Auditorium 1
Oral communications selected from abstracts
OC7 - REVISED SWEDISH FRAX MODELS AND THE ESTABLISHMENT OF AGE-DEPENDENT INTERVENTION THRESHOLDS
OC7 - REVISED SWEDISH FRAX MODELS AND THE ESTABLISHMENT OF AGE-DEPENDENT INTERVENTION THRESHOLDS
11:20
Auditorium 1
Oral communications selected from abstracts
OC8 - IMPROVED 10-YEAR FRACTURE RISK PREDICTION WITH THE “;BONE STRAIN INDEX“; BEYOND BONE MINERAL DENSITY AND FRAX® IN COMMUNITY-DWELLING OLDER WOMEN
OC8 - IMPROVED 10-YEAR FRACTURE RISK PREDICTION WITH THE “;BONE STRAIN INDEX“; BEYOND BONE MINERAL DENSITY AND FRAX® IN COMMUNITY-DWELLING OLDER WOMEN
11:30
Auditorium 1
Oral communications selected from abstracts
OC9 - EROSIVE HAND OSTEOARTHRITIS IS ASSOCIATED WITH INCREASED RISK OF INCIDENT OSTEOPOROTIC FRACTURES IN POST-MENOPAUSAL WOMEN (QUALYOR COHORT)
OC9 - EROSIVE HAND OSTEOARTHRITIS IS ASSOCIATED WITH INCREASED RISK OF INCIDENT OSTEOPOROTIC FRACTURES IN POST-MENOPAUSAL WOMEN (QUALYOR COHORT)
11:40
Auditorium 1
Oral communications selected from abstracts
OC10 - MUSCULOSKELETAL HEALTH AND LIFE-SPACE MOBILITY, SOCIAL ISOLATION AND LONELINESS IN THE OLDEST OLD: FINDINGS FROM THE HERTFORDSHIRE COHORT STUDY
OC10 - MUSCULOSKELETAL HEALTH AND LIFE-SPACE MOBILITY, SOCIAL ISOLATION AND LONELINESS IN THE OLDEST OLD: FINDINGS FROM THE HERTFORDSHIRE COHORT STUDY
11:50
Auditorium 1
Oral communications selected from abstracts
OC11 - BONE COMPONENT DISORGANIZATION IN METABOLIC AND GENETIC BONE DISEASES, INCLUDING HYPOPHOSPHATASIA: NOVEL INSIGHTS INTO DISEASE PATHOGENESIS AND PATIENT ASSESSMENT
OC11 - BONE COMPONENT DISORGANIZATION IN METABOLIC AND GENETIC BONE DISEASES, INCLUDING HYPOPHOSPHATASIA: NOVEL INSIGHTS INTO DISEASE PATHOGENESIS AND PATIENT ASSESSMENT
12:00
Auditorium 1
Oral communications selected from abstracts
OC12 - BONE COMPONENT DISORGANIZATION IN METABOLIC AND GENETIC BONE DISEASES, INCLUDING HYPOPHOSPHATASIA: NOVEL INSIGHTS INTO DISEASE PATHOGENESIS AND PATIENT ASSESSMENT
OC12 - BONE COMPONENT DISORGANIZATION IN METABOLIC AND GENETIC BONE DISEASES, INCLUDING HYPOPHOSPHATASIA: NOVEL INSIGHTS INTO DISEASE PATHOGENESIS AND PATIENT ASSESSMENT
12:15 - 13:45
Auditorium 1
Sponsored Lunch Symposium
* See details on the Sponsored Satellite Symposia page
* See details on the Sponsored Satellite Symposia page
12:15 - 13:45
Auditorium 2
Sponsored Lunch Symposium
* See details on the Sponsored Satellite Symposia page
* See details on the Sponsored Satellite Symposia page
14:00 - 15:00
Meet-The-Expert Session
14:00
MR - D9
PTH, vitamin D and bone turnover markers from the laboratory perspective: more than you can eat!
14:00
MR - D8
Skeletal microarchitecture and fracture risk
14:00
MR - D1
FLS: current global challenges
14:00
MR - D2
Managing bone health after bariatric surgery
14:00 - 15:00
MR- D4
Revolution in Osteoporosis Patient Care – Necessity, Opportunities, Possibilities and Results. The Czech Paradigm
Chairpersons: Eugene McCloskey, Vladimir Palicka, Richard Pikner
Chairpersons: Eugene McCloskey, Vladimir Palicka, Richard Pikner
14:00
MR- D4
Osteoporosis Care in the Czech Republic: where we are and where we go
14:20
MR- D4
Czech National Population Programme for Early Detection of Osteoporosis - Methodology, Principles, and 30 Months Results
14:45
MR- D4
Discussion
14:00 - 15:00
Podium
Oral presentations of selected posters
Chairperson: Elaine Dennison
Chairperson: Elaine Dennison
14:00
Podium
OP1 - P416 - FROM WRIST TO HIP: CAN EARLY FLS INTERVENTION AFTER A DISTAL RADIUS FRACTURE PREVENT THE NEXT FRAGILITY FRACTURE
14:06
Podium
OP2 - P1154 - ASSOCIATION BETWEEN THE TREATMENT-RELATED CHANGE IN BONE MINERAL DENSITY AND FRACTURE RISK REDUCTION ACCORDING TO THE PRE-TREATMENT BMD: ANALYSIS FROM THE FNIH-ASBMR SABRE PROJECT
14:12
Podium
OP3 - P1770 - REAL-WORLD TREATMENT STRATEGIES FOR OSTEOPOROSIS IN OLDER ADULTS WITH CKD-MBD: IMPACT OF GERIATRIC SYNDROMES AND TREATMENT COMPLIANCE
14:18
Podium
OP4 - P365 - GLP-1 RECEPTOR AGONISTS AND MUSCULOSKELETAL OUTCOMES: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
14:24
Podium
OP5 - P1076 - BISPHOSPHONATES OR DENOSUMAB AFTER FRACTURE? REAL-WORLD EVIDENCE FROM A TARGET TRIAL EMULATION IN MULTIMORBID ADULTS
14:36
Podium
OP7 - P806 - HIP BONE COMPARTMENT RESPONSES TO ROMOSOZUMAB VERSUS ALENDRONATE IN PATIENTS WITH DIABETES: A SUBGROUP ANALYSIS FROM THE ARCH TRIAL USING 3D-DXA MODELLING
14:42
Podium
OP8 - P261 - THE EFFECTIVENESS OF THE INTENSIVE CARE PROGRAM FOR FLS IMPLEMENTATION TO REDUCE MORPHOMETRIC VERTEBRAL FRACTURES IN OSTEOPOROSIS PATIENTS AT VERY HIGH FRACTURE RISK COMPARED TO THE PRIMARY CARE PHYSICIAN-LED STANDARD CARE: JOINT-08 TRIAL
14:48
Podium
OP9 - P1011 - BONE HEALTH IN PATIENTS WITH NON-METASTATIC PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY INTERNATIONAL OSTEOPOROSIS FOUNDATION – BONE AND CANCER WORKING GROUP – POSITION STATEMENT
14:54
Podium
OP10 - P427 - OSTEOPOROSIS AND HEARING LOSS: NATIONWIDE EVIDENCE FOR AN EXTRA-SKELETAL PROTECTIVE EFFECT OF ZOLEDRONIC ACID AND DENOSUMAB
15:00
Podium
OP11 - P739 - TRANSLATING MOLECULAR INSIGHTS INTO CLINICAL PROGRESS: RJX-01 FOR MUSCLE RECOVERY AND OSTEOSARCOPENIA THERAPY
14:00 - 15:00
MR - C1
ESCEO Symposium: GLP-1 Receptor Agonists and Musculoskeletal Health
Chairpersons: René Rizzoli, Nicholas Harvey
Chairpersons: René Rizzoli, Nicholas Harvey
14:00
MR - C1
Introduction
14:05
MR - C1
GLP1 Receptor Agonists and bone health
14:20
MR - C1
GLP1 Receptor Agonists and joint health
14:35
MR - C1
GLP1 Receptor Agonists and muscle health
14:50
MR - C1
Discussion and conclusion
14:00 - 15:00
MR - D12
ESCEO Symposium: New perspectives on clinical and regulatory aspects of sarcopenia management
Chairpersons: Nicholas Fuggle, Andrea Laslop
Chairpersons: Nicholas Fuggle, Andrea Laslop
14:00
MR - D12
Introduction
14:05
MR - D12
Sarcopenia: state of the art in disease definition and clinical translation
14:20
MR - D12
Development of novel muscle-active agents: a regulatory perspective
14:35
MR - D12
Discussion
15:00 - 16:45
MR - D12
Committee of National Societies Special Plenary Session: From Research to Clinical Practice: Bridging the Gap in Bone Health
Chairperson: Famida Jiwa
Chairperson: Famida Jiwa
15:18
MR - D12
OCs2 - REIMAGINING ROUTINE HEALTH INFORMATION SYSTEMS TO DETECT FRACTURE RISK AND OSTEOPOROSIS: A POLICY BRIEF PREPARED FOR THE WORLD HEALTH ORGANISATION (WHO)
15:26
MR - D12
OCs3 - MULTI-CENTER VALIDATION OF A FEDERATED LEARNING-BASED ARTIFICIAL INTELLIGENCE SYSTEM FOR SCREENING LOW BONE MINERAL DENSITY USING CHEST X-RAYS
15:34
MR - D12
OCs4 - GLP-1 RECEPTOR AGONISTS AND MUSCULOSKELETAL OUTCOMES: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
15:42
MR - D12
OCs5 - FRAGILITY RUNS IN THE FAMILY: INTERGENERATIONAL CLUSTERING OF OSTEOPOROSIS IN A RURAL INDIAN COHORT
15:50
MR - D12
Presentation of the IOF Committee of National Societies Medal
16:00
MR - D12
OCs6 - DEVELOPMENT AND VALIDATION OF DIABETES HIP FRACTURE SCORE (D-HFS) IN PATIENTS WITH TYPE 2 DIABETES: A POPULATION-BASED COHORT STUDY OF HONG KONG
16:08
MR - D12
OCs7 - LIFESTYLE AND CLINICAL FACTORS ASSOCIATED WITH FEMORAL NECK BONE MINERAL DENSITY IN AFRICAN ADULTS: FINDINGS FROM THE FRACTURE-E3 STUDY
16:16
MR - D12
OCs8 - USING RESEARCH TO TRANSFORM HEALTH POLICY FOR PATIENTS WITH FRAGILITY FRACTURE IN BRITISH COLUMBIA, CANADA
16:32
MR - D12
OCs10 - AI-ASSISTED OPPORTUNISTIC DETECTION OF VERTEBRAL COMPRESSION FRACTURES IN CT SCANS
15:00 - 17:00
Auditorium 1
Scientific Session III
Chairpersons: Richard Pikner, Patricia Clark
Chairpersons: Richard Pikner, Patricia Clark
15:00
Auditorium 1
Plenary Lecture
Hyperglycaemia and bone health: disease and therapy
Hyperglycaemia and bone health: disease and therapy
15:30
Auditorium 1
Oral communications selected from abstracts
OC13 - INCIDENCE OF NEW OSTEOPOROTIC FRACTURES UP TO THREE YEARS OF FOLLOW-UP IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS WHO INITIATE ANY OSTEOPOROSIS MEDICATION COMPARED TO NON-DIABETICS: A POPULATION-BASED COHORT STUDY
OC13 - INCIDENCE OF NEW OSTEOPOROTIC FRACTURES UP TO THREE YEARS OF FOLLOW-UP IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS WHO INITIATE ANY OSTEOPOROSIS MEDICATION COMPARED TO NON-DIABETICS: A POPULATION-BASED COHORT STUDY
15:40
Auditorium 1
Oral communications selected from abstracts
OC14 - TYPE 2 DIABETES MELLITUS AND FRACTURE RISK: AN INTERNATIONAL META-ANALYSIS
OC14 - TYPE 2 DIABETES MELLITUS AND FRACTURE RISK: AN INTERNATIONAL META-ANALYSIS
15:50
Auditorium 1
Oral communications selected from abstracts
OC15 - LONGITUDINAL EFFECTS OF DENOSUMAB, ROMOSOZUMAB, AND COMBINATION THERAPY ON MUSCLE QUALITY AND METABOLIC PROFILES A RANDOMIZED CONTROLLED TRIAL
OC15 - LONGITUDINAL EFFECTS OF DENOSUMAB, ROMOSOZUMAB, AND COMBINATION THERAPY ON MUSCLE QUALITY AND METABOLIC PROFILES A RANDOMIZED CONTROLLED TRIAL
16:00
Auditorium 1
Oral communications selected from abstracts
OC16 - PREGNANCY-RELATED CHANGES IN BONE HEALTH: A LONGITUDINAL REMS-BASED STUDY
OC16 - PREGNANCY-RELATED CHANGES IN BONE HEALTH: A LONGITUDINAL REMS-BASED STUDY
16:10
Auditorium 1
Oral communications selected from abstracts
OC17 - COST-EFFECTIVENESS OF AI-ENHANCED OPPORTUNISTIC OSTEOPOROSIS SCREENING USING CHEST RADIOGRAPHS: EVIDENCE FROM SIX INTERNATIONAL ANALYSES
OC17 - COST-EFFECTIVENESS OF AI-ENHANCED OPPORTUNISTIC OSTEOPOROSIS SCREENING USING CHEST RADIOGRAPHS: EVIDENCE FROM SIX INTERNATIONAL ANALYSES
16:20
Auditorium 1
Oral communications selected from abstracts
OC18 - CLINICALLY INTERPRETABLE PREDICTORS OF IMMINENT SUBSEQUENT FRACTURES IN A DEEP-LEARNING PREDICTION MODEL
OC18 - CLINICALLY INTERPRETABLE PREDICTORS OF IMMINENT SUBSEQUENT FRACTURES IN A DEEP-LEARNING PREDICTION MODEL
16:30
Auditorium 1
Plenary Lecture
Is there a role for sex hormones in the management of musculoskeletal disorders?
Is there a role for sex hormones in the management of musculoskeletal disorders?
17:00 - 18:30
Auditorium 1
Sponsored Satellite Symposium
* See details on the Sponsored Satellite Symposia page
* See details on the Sponsored Satellite Symposia page
17:00 - 18:30
Auditorium 2
Available Sponsored Satellite Symposium
* See details on the Sponsored Satellite Symposia page
* See details on the Sponsored Satellite Symposia page
18:30 - 19:30
Non-Sponsored Symposia
18:30
MR - C1
Bone Turnover Markers in CKD-Associated Osteoporosis: Translating European Consensus to Practice
Chairpersons: Maria Fusaro, Etienne Cavalier
Chairpersons: Maria Fusaro, Etienne Cavalier
18:30
MR - C1
Applying Bone Turnover Markers in Dialysis and Transplantation: Case-Based Insights
18:30
MR - C1
BALP, TRACP-5b and iPINP: New Reference Markers and Diagnostic Cut-offs in CKD
18:30
MR - D9
Clinical Outcomes of Sarcopenia: A GLIS Symposium
Chairpersons: Alfonso Cruz Jentoft, Jean-Yves Reginster
Chairpersons: Alfonso Cruz Jentoft, Jean-Yves Reginster
18:30
MR - D9
The Global Leadership Initiative on Sarcopenia (GLIS): objectives, structure, and achievements
18:30
MR - D9
Health outcomes of sarcopenia: Insights from the GLIS Outcome Working Group and clinical implications
18:30
MR - D9
Updated meta-analysis on the health outcomes of sarcopenia
18:30
MR - D12
Mind Body Exercises: Yoga and its effect on Bone and Muscle Health: Myth, Magic, or Measurable Impact?
Chairperson: Ambrish Mithal
Chairperson: Ambrish Mithal
18:30
MR - D12
Introduction to Yoga and Its Relevance to Musculoskeletal Health
18:30
MR - D12
Effect of Yoga on bone mineral metabolism
18:30
MR - D12
Effect of yoga on muscle strength
18:30
MR - D12
Yoga demonstration
18:30
MR - D12
Q&A
18:30
MR - D2
Women’s Bone Health and Hormones Therapy Update: Integrating Gynecology Into Multidisciplinary Osteoporosis Care
Chairpersons: Maria Celeste Osório Wender, Adriana Orcesi Pedro
Chairpersons: Maria Celeste Osório Wender, Adriana Orcesi Pedro
18:30
MR - D2
Estradiol Therapy in 2026: Optimizing Type, Dose, and Route for Bone Protection Across Menopausal Stages.
18:30
MR - D2
Beyond Endometrial Safety: Do Different Progestogens Change Long-Term Skeletal and Metabolic Risk?
18:30
MR - D2
Androgens and the Female Musculoskeletal System: Evidence, Gaps, and the Future of Therapy.
18:30
MR - D2
Q&A
18:30
MR - D3
Osteoporosis in Inflammatory Diseases: Clinical Challenges and Diagnostic Gaps
Chairperson: Elena Bischoff
Chairperson: Elena Bischoff
18:30
MR - D3
High prevalence of osteoporosis in autoimmune and inflammatory diseases
18:30
MR - D3
Clinical Challenges and Diagnostic Gaps: REMS technology
18:30
MR- D4
Managing Bone Fragility in Older Adults with Diabetes: Pathophysiology, Assessment, and Therapeutic Considerations in Older Adults
Chairpersons: Gulistan Bahat, Dilek Gogas Yavuz
Chairpersons: Gulistan Bahat, Dilek Gogas Yavuz
18:30
MR- D4
Pathophysiology, Risk Assessment Challenges, and Non-Pharmacological Strategies in Diabetic Bone Fragility
18:30
MR- D4
Skeletal Effects of Anti-Diabetic Drugs and Osteoporosis Management in Patients with Diabetes
18:30
MR - D1
Artificial Intelligence in Osteoporosis: What's new and what's next
Chairperson: Nicholas Fuggle
Chairperson: Nicholas Fuggle
18:30
MR - D1
The Al Landscape in Bone Health 2026: From Multimodal Models to Clinical Agents
18:30
MR - D1
Current ML models for predicting fracture risk - Do they meet the clinical need and if not then what are the next steps?
18:30
MR - D1
Ensuring Safe, Equitable, and Regulated Al in Osteoporosis Care
18:30
MR - D7
Kidney and bone health in hypoparathyroidism
Chairperson: Maria Luisa Brandi
Chairperson: Maria Luisa Brandi
18:30
MR - D7
Kidney health in hypoparathyroidism
18:30
MR - D7
Bone health in hypoparathyroidism
18:30
MR - D8
Hip Fracture and Osteoporosis
Chairperson: Christopher Niedhart
Chairperson: Christopher Niedhart
18:30
MR - D8
Hip Biomechanics and Fracture Risk: Beyond Bone Density
18:30
MR - D8
Management of Hip Fractures – The German Approach
18:30
MR - D8
Local Bone Augmentation to Prevent Hip Fractures